Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
American Diabetes Association
Headquarters: Arlington, VA, United States of America
Website: http://www.diabetes.org/
Year Founded: 1940
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Jan 18, 2025
Management Tracks
Moves at FDA, NIH
Plus: updates on AZ, Actimed, Kailera, Nasus and more
BioCentury | Nov 19, 2024
Politics, Policy & Law
Trump says he’ll nominate TV celebrity Oz to run CMS
If confirmed, promoter of pseudo-science, quack cures would be responsible for largest healthcare provider in the U.S.
BioCentury | Aug 7, 2024
Management Tracks
Flagship’s Quotient names co-founder Campbell CSO
Plus: Cellectis hires Kilcoyne and more from Helio, Sapphiros, Pharmanovia, the ADA and Outcome Capital
BioCentury | Jul 3, 2024
Discovery & Translation
Science Spotlight: Epigenetic editor for brain prion silencing, Mopac’s oral biologics and more
BioCentury’s roundup of translational innovations
BioCentury | Jun 26, 2024
Product Development
Clinical Report: Metabolic readouts from Innovent, Zealand, Poltreg
Plus: New data from Wave, G1 and Jazz
BioCentury | Jun 27, 2023
Product Development
Despite fervor, Lilly’s retatrutide not poised to supplant Mounjaro
Phase II data reveal a marginal efficacy gain but a much worse tolerability profile
BioCentury | May 10, 2023
Deals
May 10 Quick Takes: Bicycle in third radiopharma deal of year
Plus: 15% weight reduction for Boehringer, Zealand Phase II asset and updates from Aviko, DiogenX, Syneos, OliX and more
BioCentury | Mar 29, 2023
Product Development
Next up in obesity therapeutics
Late-stage pipeline dominated by large pharmas, GLP-1 combinations
BioCentury | Dec 6, 2021
Product Development
ViaCyte looking to more Type I diabetes data next year after publication
Readout shows progressive iterations of islet cell therapy after June’s promising data
BioCentury | Sep 27, 2021
Product Development
Hua’s diabetes therapy may be first to show clinical remission
Early stage Type II diabetes patients maintain HbA1c target after use of GCK activator dorzagliatin
Items per page:
1 - 10 of 625